This Valencian center, in collaboration with the PETHEMA hematology research group, affiliated with the Spanish Society of Hematology and Hemotherapy, leads a network comprising over 300 centers and 1,000 researchers. The initiative has enabled the development of a far-reaching scientific infrastructure, with patient registries and advanced diagnostic systems that accelerate understanding of the disease and the development of new therapies.
Over the past ten years, this collaboration has driven more than 120 clinical trials, allowing over 1,500 patients to access innovative treatments before their official approval. La Fe Hospital treats the highest number of acute myeloid leukemia patients annually in Spain, with between 80 and 100 new diagnoses each year. Additionally, in 2025, it received approximately 100 patients referred from other Spanish centers for alternative treatments.
“"Advancing new targeted and precision therapies is key to improving survival and reducing the adverse effects of current treatments, especially in a disease with still limited prognosis."
The hospital's research efforts are complemented by over 200 national and international projects focusing on areas such as epidemiology, targeted therapies, immunotherapy, and precision diagnostics. This research activity has a direct impact on patient health, improving diagnosis and offering early access to innovative therapies, while also contributing to the sustainability of the healthcare system.
